New Recruiting Trial: Temozolomide and Survivin Long Peptide Vaccine (SurVaxM) for the Treatment of Patients With Progressing Metastatic Neuroendocrine Carcinomas
WHY IT MATTERS
This is one of the first trials testing an immunotherapy vaccine specifically for metastatic neuroendocrine carcinomas, offering a potential new option for patients whose cancer has progressed on standard treatments.
Researchers are testing a new cancer treatment that combines two approaches: a chemotherapy drug called temozolomide and a vaccine called SurVaxM that trains the immune system to fight cancer cells. This trial is for patients with neuroendocrine carcinomas (rare cancers in hormone-producing cells) that are spreading and getting worse despite other treatments. The study is now accepting patients and will run through 2026.
NCT ID: NCT06202066 Title: Temozolomide and Survivin Long Peptide Vaccine (SurVaxM) for the Treatment of Patients With Progressing Metastatic Neuroendocrine Carcinomas Status: RECRUITING Phase: PHASE2 Sponsor: Roswell Park Cancer Institute Start date: 2026-04-15 URL: https://clinicaltrials.gov/study/NCT06202066 Source: UniteRare clinical trials database
YOU CAN ACT ON THIS
If you have metastatic neuroendocrine carcinoma that is progressing, contact Roswell Park Cancer Institute or visit clinicaltrials.gov/study/NCT06202066 to learn about enrollment requirements and whether you may qualify.